CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study
- Conditions
- Acute Rhinosinusitis
- Interventions
- Drug: beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 daysDrug: placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 166
- Registration Number
- NCT01691677
- Locations
- 🇮🇹
Policlinico Univesitario Gemelli, Roma, Italy
🇮🇹Ospedale Cisanello, Pisa, Italy
🇮🇹Policlinico Santa Maria alle Scotte, Siena, Italy
A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 36
- Registration Number
- NCT01689571
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
🇬🇧Respiratory Clinical Trials, London, United Kingdom
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children
- Conditions
- Asthma in Children
- Interventions
- Drug: combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µgDrug: free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Registration Number
- NCT01658891
- Locations
- 🇩🇰
BørneAstmaKlinikken, Copenhagen, Denmark
Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 92
- Registration Number
- NCT01651455
- Locations
- 🇮🇹
U.O. Azienda Ospedaliera, Verona, Veneto, Italy
An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device
- Conditions
- Asthma
- Interventions
- Device: Inhalation through Chiesi NEXThaler DPI
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 41
- Registration Number
- NCT01651650
- Locations
- 🇮🇹
Clinica Pneumologica, AOU di Parma, Parma, Italy
First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome
- Conditions
- Respiratory Distress Syndrome in Premature Infants
- Interventions
- Drug: synthetic surfactant (CHF5633)
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 40
- Registration Number
- NCT01651637
- Locations
- 🇬🇧
Liverpool Women's Hospital Neonatal Unit Liverpool Women's Hospital, Liverpool, United Kingdom
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: CHF 5074 2xDrug: CHF 5074 1xDrug: CHF 5074 3x
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 51
- Registration Number
- NCT01602393
- Locations
- 🇺🇸
Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States
🇺🇸Senior Adults Specialty Research, Austin, Texas, United States
🇮🇹Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy
Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children
- Conditions
- Asthma
- Interventions
- Drug: beclomethasone+formoterol 50/6 (1 inhalation)Drug: Placebo (6 inhalations)Drug: CHF 1535 50/6 (2 inhalations)Drug: CHF 1535 50/6 (4 inhalations)
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 59
- Registration Number
- NCT01584492
- Locations
- 🇺🇦
Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine
🇵🇱Poradnia Alergologiczna, Debica, Debica, Poland, Poland
Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD
- Conditions
- Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: CHF1535 daily doseDrug: CHF1535 + CHF5992 dose2 BIDDrug: CHF1535 + CHF5992 dose 1 BID
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 191
- Registration Number
- NCT01584505
- Locations
- 🇧🇬
Hospital "Lozenets", Sofia, Bulgaria
🇭🇺Fővárosi Önkormányzat Szent János Kórháza és Észak-budai Egyesített Kórházai Tüdőgondozó Szakrendelő, Budapest, Hungary
🇬🇧Medicines Evaluation Unit, Langley Building, Manchester, United Kingdom
Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
- Conditions
- Asthma
- Interventions
- Drug: CHF1535 200/6 µgDrug: BDP 100 µg
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 542
- Registration Number
- NCT01577082
- Locations
- 🇮🇹
Cardio-Thoracic and Vascular Dept, University of Pisa, Pisa, Italy